Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520466-22-00

Enrollment

Registered

2026-03-27

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Platinum-resistant Epithelial Ovarian Cancer

Brief summary

Progression free Survival (PFS): PFS is defined as the time from randomization to radiographic progression as assessed by the Investigator per RECIST v1.1, or death due to any cause.

Detailed description

Overall survival (OS): OS is defined as the time from randomisation until the date of death due to any cause.

Interventions

DRUGMIRVETUXIMAB SORAVTANSINE

DRUGDOXORUBICIN HYDROCHLORIDE

DRUGLIPOSOMAL

DRUGAZD5335

DRUGTOPOTECAN

DRUGPACLITAXEL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression free Survival (PFS): PFS is defined as the time from randomization to radiographic progression as assessed by the Investigator per RECIST v1.1, or death due to any cause.	—

Secondary

Measure	Time frame
Overall survival (OS): OS is defined as the time from randomisation until the date of death due to any cause.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 28, 2026